Emerging evidence suggests that the development of high-precision non-invasive screening tests using biomarkers to predict the risk of CRC or the early presence may contribute to the diagnosis and clinical practice of cancer, such as programmed cell death protein 1 (PD-1) and Na+/Ca2+ exchangers (NCXs) [3–6]. This evidence concerns the gene PDCD1 and colorectal carcinoma.